TPST
Tempest Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.97
+8.16%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$0.94
From 52W high−91.82%
Volume4.72M
Market cap$16.01M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$0.94
From 52W high
−91.82%
Volume
4.72M
Market cap
$16.01M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.6x
P/E (TTM)
—
RSI (14)
50.2
MomentumView details →
1D Return
+8.16%
YTD Return
−65.51%
SummaryUpdated Jun 1, 2026
Tempest Therapeutics, Inc. (NASDAQ:TPST) is a clinical-stage biotechnology company founded in 2011 and headquartered in South San Francisco, California. Originally established as a subsidiary of Inception Sciences, Inc., the company went public in November 2012. Tempest focuses on developing innovative small molecule therapeutics specifically designed to treat various forms of cancer, with a particular emphasis on targeting immune system pathways that can enhance the body's natural ability to fight tumors.
Similar companies
Latest newsMore news →
Tempest secured an exclusive option to license a clinical-stage CD7-targeted lentiviral in vivo CAR-T platform.5d agoTempest Therapeutics announced a private placement of up to $7.5 million, comprising $2.5 million upfront and up to approximately $5 million in potential gross proceeds if warrants are fully exercised.9d agoTempest Therapeutics entered into an equity line of credit agreement on August 13, 2026, committing to sell up to $50.0 million of its unregistered common stock to an accredited investor, with an initial available amount of $25.0 million and an additional $25.0 million subject to conditions.39d ago